Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2021-12 Issue:12 Volume:22 Page:1721-1731
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Banerjee Susana,Moore Kathleen N,Colombo Nicoletta,Scambia Giovanni,Kim Byoung-Gie,Oaknin Ana,Friedlander Michael,Lisyanskaya Alla,Floquet Anne,Leary Alexandra,Sonke Gabe S,Gourley Charlie,Oza Amit,González-Martín Antonio,Aghajanian Carol,Bradley William H,Holmes Eileen,Lowe Elizabeth S,DiSilvestro Paul

Funder

Merck Sharp & Dohme Ltd

AstraZeneca plc

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2013

2. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer;Tewari;J Clin Oncol,2019

3. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study;De Angelis;Lancet Oncol,2014

4. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer;Kim;J Ovarian Res,2019

5. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status;Kotsopoulos;Gynecol Oncol,2016

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group;Gynecologic Oncology;2024-05

2. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia;PLOS ONE;2024-02-01

3. Evaluation of Homologous Recombination Deficiency in Ovarian Cancer;Current Treatment Options in Oncology;2024-02-01

4. PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway;Oncogene;2024-01-31

5. Counselling Framework for Germline BRCA1/2 and PALB2 Carriers Considering Risk-Reducing Mastectomy;Current Oncology;2024-01-09